# Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Source: https://onco.cc/trials/nct06732531/  
OnCo record `nct06732531` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BH011 in bladder & urothelial cancer, run by Zhuhai Beihai Biotech Co., Ltd, now recruiting.

## Summary

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT06732531 by Zhuhai Beihai Biotech Co., Ltd, with 48 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-12. Interventions recorded: BH011.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06732531
- Phase: 1/2
- Setting: A Phase I/II, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of BH011 in Subjects With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin
- Sponsor: Zhuhai Beihai Biotech Co., Ltd
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06732531: https://clinicaltrials.gov/study/NCT06732531

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct06732531.json